Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL -2.67%38 3-1 Month Momentum % is -16.36% as of Aug. 27, 2026. GuruFocus rates AWHL with a GF Score™ of 38/100 and a GF Value™ of $0.26 (Fairly Valued). The stock has 8 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 71.5% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), Aspira Womens Health's 3-1 Month Momentum % is -16.36%.
The industry rank for Aspira Womens Health's 3-1 Month Momentum % or its related term are showing as below:
AWHL's 3-1 Month Momentum % is ranked worse than 71.5% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.74
vs AWHL: -16.36
Aspira Womens Health (OTCPK:AWHL) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Aspira Womens Health 3-1 Month Momentum % Related Terms
AWHL vs MDXH, QUCY, XWEL: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's 3-1 Month Momentum % falls into.
Aspira Womens Health (OTCPK:AWHL) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a 3-1 Month Momentum % of -16.36% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #153 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 71.5%.
Is Aspira Womens Health's 3-1 Month Momentum % too high?
Aspira Womens Health's current 3-1 Month Momentum % is -16.36%. Based on the distribution chart, Aspira Womens Health ranks #153 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Aspira Womens Health has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's 3-1 Month Momentum % compare to MDXH and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #153 out of 214 companies for 3-1 Month Momentum %. This places Aspira Womens Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current 3-1 Month Momentum % is -16.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Fairly Valued. The stock's GF Value™ is $0.26, compared to a current price of $0.26 — trading 1.1% above its estimated fair value. The current 3-1 Month Momentum % is -16.36%. Aspira Womens Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current 3-1 Month Momentum % is -16.36% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.26 is trading 1.1% above its estimated GF Value™ of $0.26.
GuruFocus considers Aspira Womens Health to be Fairly Valued.
Key valuation signals for AWHL:
3-1 Month Momentum %: -16.36%
GF Value™: $0.26 vs. price of $0.26 (1.1% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score
Get the complete analysis for AWHL
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
